Unicycive Therapeutics (UNCY) Projected to Post Earnings on Wednesday

Unicycive Therapeutics (NASDAQ:UNCY) is expected to announce its results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.4589) per share and revenue of $11.1110 million for the quarter.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.36). On average, analysts expect Unicycive Therapeutics to post $0 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Unicycive Therapeutics Price Performance

Shares of UNCY stock opened at $8.08 on Wednesday. The firm has a market cap of $215.74 million, a P/E ratio of -3.72 and a beta of 1.78. Unicycive Therapeutics has a 1-year low of $3.71 and a 1-year high of $11.00. The firm’s 50-day simple moving average is $6.91 and its 200-day simple moving average is $6.22.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Lazard Asset Management LLC acquired a new stake in Unicycive Therapeutics in the second quarter valued at approximately $55,000. JPMorgan Chase & Co. grew its position in Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after acquiring an additional 21,525 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Unicycive Therapeutics in the third quarter valued at approximately $182,000. Quadrature Capital Ltd acquired a new stake in Unicycive Therapeutics in the fourth quarter valued at approximately $226,000. Finally, State Street Corp grew its position in Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after acquiring an additional 10,400 shares in the last quarter. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on UNCY shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, March 27th. Benchmark cut their price objective on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating on the stock in a report on Monday, April 6th. Guggenheim cut their price objective on shares of Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Westpark Capital started coverage on shares of Unicycive Therapeutics in a report on Thursday, February 19th. They set a “buy” rating on the stock. Finally, Wall Street Zen lowered shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Unicycive Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $24.75.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.